Zydus receives final approval from the USFDA for Desoximetasone Cream USP

Deepthi | Myequity news | Date : 01-10-2018 13:20:00 IST

Zydus Cadila has received the final approval from the USFDA to market Desoximetasone Cream USP (US RLD Topicort® Cream), 0.25%. It will be manufactured at the group’s Topical manufacturing facility at Ahmedabad.

Desoximetasone is a strong corticosteroid, used to treat a variety of skin conditions (e.g., eczema, dermatitis, allergies and rash). It reduces the swelling, itching and redness that can occur in these types of conditions.

The group now has 219 approvals and has so far filed over 330 ANDAs since the commencement of the filing process in FY 2003-04.

About Zydus Cadila:

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs nearly 23,000 people worldwide and is dedicated to creating healthier communities globally.

More from Myequity